12 results on '"van Ommen, Gert-Jan"'
Search Results
2. Therapeutic exon skipping for dysferlinopathies?
- Author
-
Aartsma-Rus, Annemieke, Singh, Kavita H. K., Fokkema, Ivo F. A. C., Ginjaar, Ieke B., van Ommen, Gert-Jan, den Dunnen, Johan T., and van der Maarel, Silvère M.
- Subjects
EXONS (Genetics) ,DUCHENNE muscular dystrophy ,CLINICAL trials ,OLIGONUCLEOTIDES ,PROTEINS - Abstract
Antisense-mediated exon skipping is a promising therapeutic approach for Duchenne muscular dystrophy (DMD) currently tested in clinical trials. The aim is to reframe dystrophin transcripts using antisense oligonucleotides (AONs). These hide an exon from the splicing machinery to induce exon skipping, restoration of the reading frame and generation of internally deleted, but partially functional proteins. It thus relies on the characteristic of the dystrophin protein, which has essential N- and C-terminal domains, whereas the central rod domain is largely redundant. This approach may also be applicable to limb-girdle muscular dystrophy type 2B (LGMD2B), Myoshi myopathy (MM) and distal myopathy with anterior tibial onset (DMAT), which are caused by mutations in the dysferlin-encoding DYSF gene. Dysferlin has a function in repairing muscle membrane damage. Dysferlin contains calcium-dependent C2 lipid binding (C2) domains and an essential transmembrane domain. However, mildly affected patients in whom one or a large number of DYSF exons were missing have been described, suggesting that internally deleted dysferlin proteins can be functional. Thus, exon skipping might also be applicable as a LGMD2B, MM and DMAT therapy. In this study we have analyzed the dysferlin protein domains and DYSF mutations and have described what exons are promising targets with regard to applicability and feasibility. We also show that DYSF exon skipping seems to be as straightforward as DMD exon skipping, as AONs to induce efficient skipping of four DYSF exons were readily identified. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
3. Development of Antisense-Mediated Exon Skipping as a Treatment for Duchenne Muscular Dystrophy.
- Author
-
Heemskerk, Hans, de Winter, Christa L., van Ommen, Gert‐Jan B., van Deutekom, Judith C.T., and Aartsma‐Rus, Annemieke
- Subjects
TREATMENT of Duchenne muscular dystrophy ,ANTISENSE nucleic acids ,EXONS (Genetics) ,DYSTROPHIN genes ,OLIGONUCLEOTIDES ,CELL culture ,LABORATORY mice ,LABORATORY dogs ,THERAPEUTICS - Abstract
Duchenne muscular dystrophy (DMD) is a severe muscle-wasting disease caused by frame shifting and nonsense mutations in the dystrophin gene. Through skipping of an (additional) exon from the pre-mRNA, the reading frame can be restored. This can be achieved with antisense oligonucleotides (AONs), which induce exon skipping by binding to splice sites or splice enhancer sites. The resulting protein will be shorter but at least partially functional. So far, exon skipping has been very successful in cell cultures, in mouse and dog models, and even in a first exploratory study in patients. Current research mainly focuses on optimization of systemic AON delivery. Here we give an overview of the available mouse models. To obtain the most informative results for future clinical application, research may have to move from the currently preferred mdx mouse to mouse models more comparable to patients, such as the utrophin/dystrophin-negative mouse and the hDMD mouse models. Further, we briefly discuss two AON backbone chemistries that are currently in clinical trials for DMD exon skipping. We propose that different chemistries should be further developed in parallel in order to hasten the transfer of the exon skipping therapy to the clinic. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
4. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
- Author
-
Aartsma-Rus, Annemieke, Janson, Anneke A. M., van Ommen, Gert-Jan B., and van Deutekom, Judith C. T.
- Subjects
DUCHENNE muscular dystrophy ,EXONS (Genetics) ,MUSCLE cells ,DYSTROPHIN ,GENETIC mutation - Abstract
Background: Antisense-mediated exon skipping is currently one of the most promising therapeutic approaches for Duchenne muscular dystrophy (DMD). Using antisense oligonucleotides (AONs) targeting specific exons the DMD reading frame is restored and partially functional dystrophins are produced. Following proof of concept in cultured muscle cells from patients with various deletions and point mutations, we now focus on single and multiple exon duplications. These mutations are in principle ideal targets for this approach since the specific skipping of duplicated exons would generate original, full-length transcripts. Methods: Cultured muscle cells from DMD patients carrying duplications were transfected with AONs targeting the duplicated exons, and the dystrophin RNA and protein were analyzed. Results: For two brothers with an exon 44 duplication, skipping was, even at suboptimal transfection conditions, so efficient that both exons 44 were skipped, thus generating, once more, an out-of-frame transcript. In such cases, one may resort to multi-exon skipping to restore the reading frame, as is shown here by inducing skipping of exon 43 and both exons 44. By contrast, in cells from a patient with an exon 45 duplication we were able to induce single exon 45 skipping, which allowed restoration of wild type dystrophin. The correction of a larger duplication (involving exons 52 to 62), by combinations of AONs targeting the outer exons, appeared problematic due to inefficient skipping and mistargeting of original instead of duplicated exons. Conclusion: The correction of DMD duplications by exon skipping depends on the specific exons targeted. Its options vary from the ideal one, restoring for the first time the true, wild type dystrophin, to requiring more 'classical' skipping strategies, while the correction of multi-exon deletions may need the design of tailored approaches. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
5. Advances in therapeutic RNA-targeting
- Author
-
van Ommen, Gert-Jan B. and Aartsma-Rus, Annemieke
- Subjects
- *
THERAPEUTICS , *GENE targeting , *MESSENGER RNA , *OLIGONUCLEOTIDES , *EXONS (Genetics) , *CLINICAL trials , *MUSCULAR dystrophy - Abstract
This paper reviews the advances in the past decade of different applications of modulating the level and content of mRNA by antisense oligonucleotide (AON)-based exon skipping. The primary aim of such modulation is the correction of genetic defects by alteration of the resulting protein such that the dysfunction is reduced or relieved. This application is in several clinical phase III trails, notably for Duchenne muscular dystrophy and earlier clinical trials are in preparation for other diseases, a.o. spinal muscular atrophy. An alternative aim may be to disrupt the reading frame of dysfunctional proteins when they have a dominant negative effect and their absence may ameliorate disease. A third aim is to target mRNAs for other proteins, the engineering of which might improve or prevent the disease. A final application, which is as yet under-explored but has major promise, is the functional in vivo study of protein isoforms by modulating their relative levels by AON-based skipping of alternative exons. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
6. Exon skipping for DMD.
- Author
-
Aartsma-Rus, Annemieke, Verschuuren, Jan J. G. M., Campion, Giles V., van Ommen, Gert-jan B., and van Deutekom, Judith C. T.
- Subjects
EXONS (Genetics) ,DUCHENNE muscular dystrophy - Abstract
An abstract of the article "Exon skipping for DMD," by Annemieke Aartsma-Rus and colleagues is presented.
- Published
- 2012
- Full Text
- View/download PDF
7. Enhanced Exon-skipping Induced by U7 snRNA Carrying a Splicing Silencer Sequence: Promising Tool for DMD Therapy.
- Author
-
Goyenvalle, Aurélie, Babbs, Arran, van Ommen, Gert-Jan B., Garcia, Luis, and Davies, Kay E.
- Subjects
- *
EXONS (Genetics) , *DUCHENNE muscular dystrophy , *MESSENGER RNA , *DYSTROPHIN genes , *GENE therapy , *OLIGONUCLEOTIDES , *DYSTROPHY - Abstract
Duchenne muscular dystrophy (DMD) is a fatal muscle wasting disorder caused by mutations in the dystrophin gene. In most cases, the open-reading frame is disrupted which results in the absence of functional protein. Antisense-mediated exon skipping is one of the most promising approaches for the treatment of DMD and has recently been shown to correct the reading frame and restore dystrophin expression in vitro and in vivo. Specific exon skipping can be achieved using synthetic oligonucleotides or viral vectors encoding modified small nuclear RNAs (snRNAs), by masking important splicing sites. In this study, we demonstrate that enhanced exon skipping can be induced by a U7 snRNA carrying binding sites for the heterogeneous ribonucleoprotein A1 (hnRNPA1). In DMD patient cells, bifunctional U7 snRNAs harboring silencer motifs induce complete skipping of exon 51, and thus restore dystrophin expression to near wild-type levels. Furthermore, we show the efficacy of these constructs in vivo in transgenic mice carrying the entire human DMD locus after intramuscular injection of adeno-associated virus (AAV) vectors encoding the bifunctional U7 snRNA. These new constructs are very promising for the optimization of therapeutic exon skipping for DMD, but also offer powerful and versatile tools to modulate pre-mRNA splicing in a wide range of applications.Molecular Therapy (2009) 17 7, 1234–1240. doi:10.1038/mt.2009.113 [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
8. Preventing Formation of Toxic N-Terminal Huntingtin Fragments Through Antisense Oligonucleotide-Mediated Protein Modification.
- Author
-
Evers, Melvin M., Tran, Hoang-Dai, Zalachoras, Ioannis, Meijer, Onno C., den Dunnen, Johan T., van Ommen, Gert-Jan B., Aartsma-Rus, Annemieke, and van Roon-Mom, Willeke M.C.
- Subjects
- *
HUNTINGTON disease , *ANTISENSE genetics , *EXONS (Genetics) , *POLYGLUTAMINE , *HUNTINGTIN protein , *OLIGONUCLEOTIDES - Abstract
Huntington's disease (HD) is a progressive autosomal dominant disorder, caused by a CAG repeat expansion in the HTT gene, which results in expansion of a polyglutamine stretch at the N-terminal end of the huntingtin protein. Several studies have implicated the importance of proteolytic cleavage of mutant huntingtin in HD pathogenesis and it is generally accepted that N-terminal huntingtin fragments are more toxic than full-length protein. Important cleavage sites are encoded by exon 12 of HTT. Here we report proof of concept using antisense oligonucleotides to induce skipping of exon 12 in huntingtin pre-mRNA, thereby preventing the formation of a 586 amino acid N-terminal huntingtin fragment implicated in HD toxicity. In vitro studies showed successful exon skipping and appearance of a shorter huntingtin protein. Cleavage assays showed reduced 586 amino acid N-terminal huntingtin fragments in the treated samples. In vivo studies revealed exon skipping after a single injection of antisense oligonucleotides in the mouse striatum. Recent advances to inhibit the formation of mutant huntingtin using oligonucleotides seem promising therapeutic strategies for HD. Nevertheless, huntingtin is an essential protein and total removal has been shown to result in progressive neurodegeneration in vivo. Our proof of concept shows a completely novel approach to reduce mutant huntingtin toxicity not by reducing its expressing levels, but by modifying the huntingtin protein. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Prednisolone Treatment Does Not Interfere with 2′-O-Methyl Phosphorothioate Antisense-Mediated Exon Skipping in Duchenne Muscular Dystrophy.
- Author
-
Verhaart, Ingrid E.C., Heemskerk, Hans, Karnaoukh, Tatyana G., Kolfschoten, Ingrid G.M., Vroon, Anne, van Ommen, Gert-Jan B., van Deutekom, Judith C.T., and Aartsma-Rus, Annemieke
- Subjects
- *
TREATMENT of Duchenne muscular dystrophy , *ADRENOCORTICAL hormones , *PREDNISONE , *LABORATORY mice , *MESSENGER RNA , *GENE expression , *EXONS (Genetics) - Abstract
AbstractIn Duchenne muscular dystrophy (DMD), dystrophin deficiency leading to progressive muscular degeneration is caused by frame-shifting mutations in the DMDgene. Antisense oligonucleotides (AONs) aim to restore the reading frame by skipping of a specific exon(s), thereby allowing the production of a shorter, but semifunctional protein, as is found in the mostly more mildly affected patients with Becker muscular dystrophy. AONs are currently being investigated in phase 3 placebo-controlled clinical trials. Most of the participating patients are treated symptomatically with corticosteroids (mainly predniso[lo]ne) to stabilize the muscle fibers, which might affect the uptake and/or efficiency of AONs. Therefore the effect of prednisolone on 2′-O-methyl phosphorothioate AON efficacy in patient-derived cultured muscle cells and the mdxmouse model (after local and systemic AON treatment) was assessed in this study. Both in vitroand in vivoskip efficiency and biomarker expression were comparable between saline- and prednisolone-cotreated cells and mice. After systemic exon 23-specific AON (23AON) treatment for 8 weeks, dystrophin was detectable in all treated mice. Western blot analyses indicated slightly higher dystrophin levels in prednisolone-treated mice, which might be explained by better muscle condition and consequently more target dystrophin pre-mRNA. In addition, fibrotic and regeneration biomarkers were normalized to some extent in prednisolone- and/or 23AON-treated mice. Overall these results show that the use of prednisone forms no barrier to participation in clinical trials with AONs. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
10. Guidelines for Antisense Oligonucleotide Design and Insight Into Splice-modulating Mechanisms.
- Author
-
Aartsma-Rus, Annemieke, van Vliet, Laura, Hirschi, Marscha, Janson, Anneke A. M., Heemskerk, Hans, de Winter, Christa L., de Kimpe, Sjef, van Deutekom, Judith C. T., 't Hoen, Peter A. C., and van Ommen, Gert-Jan B.
- Subjects
- *
OLIGONUCLEOTIDES , *MESSENGER RNA , *ANTISENSE RNA , *RIBONUCLEASES , *EXONS (Genetics) , *DYSTROPHIN genes - Abstract
Antisense oligonucleotides (AONs) can interfere with mRNA processing through RNase H–mediated degradation, translational arrest, or modulation of splicing. The antisense approach relies on AONs to efficiently bind to target sequences and depends on AON length, sequence content, secondary structure, thermodynamic properties, and target accessibility. We here performed a retrospective analysis of a series of 156 AONs (104 effective, 52 ineffective) previously designed and evaluated for splice modulation of the dystrophin transcript. This showed that the guanine-cytosine content and the binding energies of AON-target and AON–AON complexes were significantly higher for effective AONs. Effective AONs were also located significantly closer to the acceptor splice site (SS). All analyzed AONs are exon-internal and may act through steric hindrance of Ser-Arg-rich (SR) proteins to exonic splicing enhancer (ESE) sites. Indeed, effective AONs were significantly enriched for ESEs predicted by ESE software programs, except for predicted binding sites of SR protein Tra2β, which were significantly enriched in ineffective AONs. These findings compile guidelines for development of AONs and provide more insight into the mechanism of antisense-mediated exon skipping. On the basis of only four parameters, we could correctly classify 79% of all AONs as effective or ineffective, suggesting these parameters can be used to more optimally design splice-modulating AONs.Molecular Therapy (2009) 17 3, 548–553 doi:10.1038/mt.2008.205 [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
11. Exploring the Frontiers of Therapeutic Exon Skipping for Duchenne Muscular Dystrophy by Double Targeting within One or Multiple Exons.
- Author
-
Aartsma-Rus, Annemieke, Kaman, Wendy E., Weij, Rudie, den Dunnen, Johan T., van Ommen, Gert-Jan. B., and van Deutekom, Judith C. T.
- Subjects
- *
EXONS (Genetics) , *GENE therapy , *DYSTROPHIN genes , *DUCHENNE muscular dystrophy - Abstract
Through antisense-induced single-, double-, and multiexon skipping, we have previously demonstrated restoration of dystrophin expression in Duchenne muscular dystrophy (DMD) patient-derived muscle cells in vitro. In this study we further explored the frontiers of this strategy by using specific combinations of 2′-O-methyl phosphorothioate antisense oligonucleotides (AONs) targeting either one or multiple exons. We show that skipping efficiencies may indeed be improved by targeting two putative splicing regulatory sequences within one exon. In particular, such double targeting was effective for the thus far “unskippable” exons 47 and 57. We previously reported the feasibility of multiexon skipping spanning exon 45 to exon 51, using a combination of AONs targeting both outer exons (45 and 51). This would be applicable to 13% of all DMD patients. We here explored the frontiers of multiexon skipping both to increase the number of patients that can be treated with the same set of AONs and to mimic large deletions found in relatively mildly affected BMD patients. We aimed at inducing larger multiexon-skipping stretches, such as exons 17–51, exons 42–55, and exons 45–59. However, this appeared complicated and may be dependent on cotranscriptional splicing and the size of the flanking introns.Molecular Therapy (2006) 14, 401–407; doi: 10.1016/j.ymthe.2006.02.022 [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
12. Antisense-Induced Multiexon Skipping for Duchenne Muscular Dystrophy Makes More Sense.
- Author
-
Aartsma-Rus, Annemieke, Janson, Anneke A. M., Kaman, Wendy E., Bremmer-Bout, Mattie, van Ommen, Gert-Jan B., Johan T. den Dunnen, and van Deutekom, Judith C. T.
- Subjects
- *
MUSCULAR dystrophy , *GENETIC disorders , *EXONS (Genetics) , *GENES , *HUMAN genetics , *MEDICAL genetics - Abstract
Dystrophin deficiency, which leads to severe and progressive muscle degeneration in patients with Duchenne muscular dystrophy (DMD), is caused by frameshifting mutations in the dystrophin gene. A relatively new therapeutic strategy is based on antisense oligonucleotides (AONs) that induce the specific skipping of a single exon, such that the reading frame is restored. This allows the synthesis of a largely functional dystrophin, associated with a milder Becker muscular dystrophy phenotype. We have previously successfully targeted 20 different DMD exons that would, theoretically, be beneficial for >75% of all patients. To further enlarge this proportion, we here studied the feasibility of double and multiexon skipping. Using a combination of AONs, double skipping of exon 43 and 44 was induced, and dystrophin synthesis was restored in myotubes from one patient affected by a nonsense mutation in exon 43. For another patient, with an exon 46–50 deletion, the therapeutic double skipping of exon 45 and 51 was achieved. Remarkably, in control myotubes, the latter combination of AONs caused the skipping of the entire stretch of exons from 45 through 51. This in-frame multiexon skipping would be therapeutic for a series of patients carrying different DMD-causing mutations. In fact, we here demonstrate its feasibility in myotubes from a patient with an exon 48–50 deletion. The application of multiexon skipping may provide a more uniform methodology for a larger group of patients with DMD. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.